U-0126

SynDRA canonical compound SYN0003818 — structure-anchored drug synonym record

Clinical phase	Preclinical
Primary target(s)	AKT1 \| CHEK1 \| GSK3B \| JAK2 \| LCK \| MAP2K1 \| MAP2K2 \| MAP2K7 \| MAPK1 \| MAPK11 \| MAPK12 \| MAPK14 \| MAPK8 \| PRKCA \| RAF1 \| ROCK1 \| RPS6KB1 \| SGK1
Mechanism of action	MEK inhibitor

All known targets

AKT1
CHEK1
RPS6KB1
ROCK1
RAF1
PRKCA
MAPK8
MAPK14
MAPK12
MAPK11
MAPK1
MAP3K2

Mechanisms of action (all sources)

MEK inhibitor
MAP3K2 INHIBITOR
MAP3K1 INHIBITOR

Cross-references

PubChem CID: 3006531
ChEMBL: CHEMBL100473
ChEBI: 64208
TTD: D0GD8Y

Synonyms

U0126
U 0126
1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene
UNII-8027P94HLL
CHEBI:64208
8027P94HLL
(2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile
FT-1069-1
Succinonitrile, bis(amino(o-aminophenylthio)methylene)-
Butanedinitrile, bis(amino((2-aminophenyl)thio)methylene)-
C18H16N6S2
(2z)-Bis{amino[(2-Aminophenyl)sulfanyl]methylidene}butanedinitrile
(2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile
MFCD01861186
Tocris-1144
Lopac-U-120
MFCD09971039
NCGC00016074-01
NCGC00025029-01
AC-28464
BRD-K91701654-001-01-5
BRD-K91701654-001-02-3
BRD-K91701654-001-03-1
U0126 >99%

Look up U-0126 in the interactive SynDRA portal →